News

Several issues of the new legislation regulating clinical trials and studies started by investigators have been explored from a practical approach during the ‘Conference on Clinical Trials’ organized by the European University and BioClever.

On Wednesday 17th of February 2016, in an effort to provide students with high-quality, relevant, humanistic education,  Francisco de Vitoria University of Madrid organized a conference on the importance, role and impact of vaccines not only in developed countries, like ours, but also in developing countries.

To conduct a clinical trial, electronic data collection is currently becoming more common, because new technologies enable us to gather information in a faster and more streamlined way, with the quality assurance required by the end purpose of collecting such data.

The legislation regulating the marketing of medical devices defines them as “any instrument, device, equipment, software, material or any other item intended for specific diagnostic and/or therapeutic purposes by its manufacturer”.

BioClever CRO, together with the European University of Madrid, hosted a coaching event given by Álvaro Merino on “new models of leadership, management and motivation for individuals and work teams”.

BioClever is a Contract Research Organization (CRO) founded in 2005, but whose origins can be traced back to old Biomedical Systems, one of the first CROs established in our country.

We have participated in the REVASCAT trial, which has revealed the benefits of a new treatment for ischemic stroke.

BioClever CRO is the sponsor of this  1ª edition of the Most Outstanding Undergraduate Pharmacy Student Award of the Francisco de Vitoria University of Madrid.

In the Spanish pharmaceutical and medical service sector, it has become increasingly popular to work with companies specialized in clinical trials that offer their services as CROs (Contract Research Organizations).

At the 11th Congress held by the Medical Association of the Pharmaceutical Industry (AMIFE, as per the Spanish acronym), held on November 12-14 in Madrid, one of the issues discussed was the status of the Clinical Trial Royal Decree, which is currently awaiting the ruling of the State Council, since the text is almost finished, as stated by Mr. César Hernández, Head of the Committee on Medicinal Products for Human Use of the Spanish Agency of Medicinal Products and Medical Devices (AEMPS).

Clinical trials are complex, because pharmaceutical and biotechnological companies follow the strictest testing for what is the fruit of their time, resources, talents and creativity, always in compliance with applicable national and international policies and regulations.

In the last few years, research had migrated to countries in the Far East and to the United States.